Activated and regulatory T lymphocyte populations in chronic hemodialysis patients

Hamid Rabb, S. J. Agosti, S. Pollard, P. A. Bittle, G. Ramirez

Research output: Contribution to journalArticle

Abstract

T lymphocyte activation after leukocyte membrane interaction may play a role in immune dysfunction associated with hemodialysis (HD). Studies of T- lymphocyte activation markers in HD have yielded conflicting results, perhaps due to the use of a limited number of markers and different measurement techniques. We studied the lymphocyte activation markers CD25 (interleukin-2 receptor), CD38, CDw49b (VLA-2), CD71 (transferrin receptor), and HLA-DR, as well as the surface antigens CD3, CD4, CD7, and CD8 by two-color flow cytometry in 23 chronic HD patients before and after a single dialysis session; we also studied 30 normal controls. There was no increase in the percentage of activated T cells in the controls and in the patients pre- and post-HD. Conversely, the percentage of CD3+/CD71+ (transferrin receptor) cells was significantly decreased in the patients pre-HD compared with the controls (3.6% ± 0.5% [mean ± SEM] v 5.9% ± 0.5%; P <0.005). A single dialysis session did not alter the percentage of activated subsets, but led to significant depletion in the number (x109/L) of cells that were CD3+ (1.10 ± 0.10 v 0.97 ± 0.09; P <0.05), CD7+ (1.0 ± 0.09 v 0.85 ± 0.08; P <0.0001), and CD8+ (0.50 ± 0.06 v 0.37 ± 0.04; P <0.001), but not CD4+ cells (0.73 ± 0.08 v 0.69 ± 0.07; P = NS). These data indicate that the chronic HD patients at baseline 'predialysis' do not appear to have an increased percentage of circulating activated T lymphocyte subsets and that the CD3+/CD71+ subset is in fact decreased. Moreover, a single dialysis session results in depletion of select lymphocyte subsets, including CD7 and CD8, which may play a role in the immunologic dysfunction in HD patients.

Original languageEnglish (US)
Pages (from-to)443-452
Number of pages10
JournalAmerican Journal of Kidney Diseases
Volume24
Issue number3
StatePublished - 1994
Externally publishedYes

Fingerprint

Regulatory T-Lymphocytes
Renal Dialysis
Population
Lymphocyte Activation
Dialysis
Transferrin Receptors
T-Lymphocytes
Integrin alpha2beta1
Interleukin-2 Receptors
Lymphocyte Subsets
T-Lymphocyte Subsets
HLA-DR Antigens
Surface Antigens
Flow Cytometry
Leukocytes
Color
Membranes

ASJC Scopus subject areas

  • Nephrology

Cite this

Rabb, H., Agosti, S. J., Pollard, S., Bittle, P. A., & Ramirez, G. (1994). Activated and regulatory T lymphocyte populations in chronic hemodialysis patients. American Journal of Kidney Diseases, 24(3), 443-452.

Activated and regulatory T lymphocyte populations in chronic hemodialysis patients. / Rabb, Hamid; Agosti, S. J.; Pollard, S.; Bittle, P. A.; Ramirez, G.

In: American Journal of Kidney Diseases, Vol. 24, No. 3, 1994, p. 443-452.

Research output: Contribution to journalArticle

Rabb, H, Agosti, SJ, Pollard, S, Bittle, PA & Ramirez, G 1994, 'Activated and regulatory T lymphocyte populations in chronic hemodialysis patients', American Journal of Kidney Diseases, vol. 24, no. 3, pp. 443-452.
Rabb, Hamid ; Agosti, S. J. ; Pollard, S. ; Bittle, P. A. ; Ramirez, G. / Activated and regulatory T lymphocyte populations in chronic hemodialysis patients. In: American Journal of Kidney Diseases. 1994 ; Vol. 24, No. 3. pp. 443-452.
@article{703cb97ef7c54294b18746857c77921c,
title = "Activated and regulatory T lymphocyte populations in chronic hemodialysis patients",
abstract = "T lymphocyte activation after leukocyte membrane interaction may play a role in immune dysfunction associated with hemodialysis (HD). Studies of T- lymphocyte activation markers in HD have yielded conflicting results, perhaps due to the use of a limited number of markers and different measurement techniques. We studied the lymphocyte activation markers CD25 (interleukin-2 receptor), CD38, CDw49b (VLA-2), CD71 (transferrin receptor), and HLA-DR, as well as the surface antigens CD3, CD4, CD7, and CD8 by two-color flow cytometry in 23 chronic HD patients before and after a single dialysis session; we also studied 30 normal controls. There was no increase in the percentage of activated T cells in the controls and in the patients pre- and post-HD. Conversely, the percentage of CD3+/CD71+ (transferrin receptor) cells was significantly decreased in the patients pre-HD compared with the controls (3.6{\%} ± 0.5{\%} [mean ± SEM] v 5.9{\%} ± 0.5{\%}; P <0.005). A single dialysis session did not alter the percentage of activated subsets, but led to significant depletion in the number (x109/L) of cells that were CD3+ (1.10 ± 0.10 v 0.97 ± 0.09; P <0.05), CD7+ (1.0 ± 0.09 v 0.85 ± 0.08; P <0.0001), and CD8+ (0.50 ± 0.06 v 0.37 ± 0.04; P <0.001), but not CD4+ cells (0.73 ± 0.08 v 0.69 ± 0.07; P = NS). These data indicate that the chronic HD patients at baseline 'predialysis' do not appear to have an increased percentage of circulating activated T lymphocyte subsets and that the CD3+/CD71+ subset is in fact decreased. Moreover, a single dialysis session results in depletion of select lymphocyte subsets, including CD7 and CD8, which may play a role in the immunologic dysfunction in HD patients.",
author = "Hamid Rabb and Agosti, {S. J.} and S. Pollard and Bittle, {P. A.} and G. Ramirez",
year = "1994",
language = "English (US)",
volume = "24",
pages = "443--452",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Activated and regulatory T lymphocyte populations in chronic hemodialysis patients

AU - Rabb, Hamid

AU - Agosti, S. J.

AU - Pollard, S.

AU - Bittle, P. A.

AU - Ramirez, G.

PY - 1994

Y1 - 1994

N2 - T lymphocyte activation after leukocyte membrane interaction may play a role in immune dysfunction associated with hemodialysis (HD). Studies of T- lymphocyte activation markers in HD have yielded conflicting results, perhaps due to the use of a limited number of markers and different measurement techniques. We studied the lymphocyte activation markers CD25 (interleukin-2 receptor), CD38, CDw49b (VLA-2), CD71 (transferrin receptor), and HLA-DR, as well as the surface antigens CD3, CD4, CD7, and CD8 by two-color flow cytometry in 23 chronic HD patients before and after a single dialysis session; we also studied 30 normal controls. There was no increase in the percentage of activated T cells in the controls and in the patients pre- and post-HD. Conversely, the percentage of CD3+/CD71+ (transferrin receptor) cells was significantly decreased in the patients pre-HD compared with the controls (3.6% ± 0.5% [mean ± SEM] v 5.9% ± 0.5%; P <0.005). A single dialysis session did not alter the percentage of activated subsets, but led to significant depletion in the number (x109/L) of cells that were CD3+ (1.10 ± 0.10 v 0.97 ± 0.09; P <0.05), CD7+ (1.0 ± 0.09 v 0.85 ± 0.08; P <0.0001), and CD8+ (0.50 ± 0.06 v 0.37 ± 0.04; P <0.001), but not CD4+ cells (0.73 ± 0.08 v 0.69 ± 0.07; P = NS). These data indicate that the chronic HD patients at baseline 'predialysis' do not appear to have an increased percentage of circulating activated T lymphocyte subsets and that the CD3+/CD71+ subset is in fact decreased. Moreover, a single dialysis session results in depletion of select lymphocyte subsets, including CD7 and CD8, which may play a role in the immunologic dysfunction in HD patients.

AB - T lymphocyte activation after leukocyte membrane interaction may play a role in immune dysfunction associated with hemodialysis (HD). Studies of T- lymphocyte activation markers in HD have yielded conflicting results, perhaps due to the use of a limited number of markers and different measurement techniques. We studied the lymphocyte activation markers CD25 (interleukin-2 receptor), CD38, CDw49b (VLA-2), CD71 (transferrin receptor), and HLA-DR, as well as the surface antigens CD3, CD4, CD7, and CD8 by two-color flow cytometry in 23 chronic HD patients before and after a single dialysis session; we also studied 30 normal controls. There was no increase in the percentage of activated T cells in the controls and in the patients pre- and post-HD. Conversely, the percentage of CD3+/CD71+ (transferrin receptor) cells was significantly decreased in the patients pre-HD compared with the controls (3.6% ± 0.5% [mean ± SEM] v 5.9% ± 0.5%; P <0.005). A single dialysis session did not alter the percentage of activated subsets, but led to significant depletion in the number (x109/L) of cells that were CD3+ (1.10 ± 0.10 v 0.97 ± 0.09; P <0.05), CD7+ (1.0 ± 0.09 v 0.85 ± 0.08; P <0.0001), and CD8+ (0.50 ± 0.06 v 0.37 ± 0.04; P <0.001), but not CD4+ cells (0.73 ± 0.08 v 0.69 ± 0.07; P = NS). These data indicate that the chronic HD patients at baseline 'predialysis' do not appear to have an increased percentage of circulating activated T lymphocyte subsets and that the CD3+/CD71+ subset is in fact decreased. Moreover, a single dialysis session results in depletion of select lymphocyte subsets, including CD7 and CD8, which may play a role in the immunologic dysfunction in HD patients.

UR - http://www.scopus.com/inward/record.url?scp=0028095143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028095143&partnerID=8YFLogxK

M3 - Article

C2 - 7915875

AN - SCOPUS:0028095143

VL - 24

SP - 443

EP - 452

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -